258 related articles for article (PubMed ID: 22027694)
21. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
24. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
[TBL] [Abstract][Full Text] [Related]
25. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
[TBL] [Abstract][Full Text] [Related]
26. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Sissung TM; Danesi R; Kirkland CT; Baum CE; Ockers SB; Stein EV; Venzon D; Price DK; Figg WD
J Clin Endocrinol Metab; 2011 Feb; 96(2):E368-72. PubMed ID: 21106711
[TBL] [Abstract][Full Text] [Related]
28. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
[TBL] [Abstract][Full Text] [Related]
29. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
[TBL] [Abstract][Full Text] [Related]
31. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Huber RM; Lucas JM; Gomez-Sarosi LA; Coleman I; Zhao S; Coleman R; Nelson PS
Oncotarget; 2015 Feb; 6(4):2134-47. PubMed ID: 25575823
[TBL] [Abstract][Full Text] [Related]
32. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
33. Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C; Heller M; Endris V; Volckmar AL; Zschäbitz S; Tapia-Laliena MA; Duensing A; Jäger D; Schirmacher P; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
Sci Rep; 2017 Jul; 7(1):4574. PubMed ID: 28676659
[TBL] [Abstract][Full Text] [Related]
34. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
35. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells.
Zu S; Ma W; Xiao P; Cui Y; Ma T; Zhou C; Zhang H
Urol Int; 2015; 95(1):114-9. PubMed ID: 25999365
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
[TBL] [Abstract][Full Text] [Related]
38. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
[TBL] [Abstract][Full Text] [Related]
39. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Puhr M; Hoefer J; Neuwirt H; Eder IE; Kern J; Schäfer G; Geley S; Heidegger I; Klocker H; Culig Z
Oncotarget; 2014 Dec; 5(23):12043-56. PubMed ID: 25474038
[TBL] [Abstract][Full Text] [Related]
40. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
